Cargando…
Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular Carcinoma
SIMPLE SUMMARY: Skeletal muscle volume has been reported as a prognostic factor for patients with hepatocellular carcinoma receiving sorafenib. In this study, we show that skeletal muscle volume is not only a predictor of overall survival but also of post-progression survival, which represents survi...
Autores principales: | Saeki, Issei, Yamasaki, Takahiro, Yamauchi, Yurika, Takami, Taro, Kawaoka, Tomokazu, Uchikawa, Shinsuke, Hiramatsu, Akira, Aikata, Hiroshi, Kawano, Reo, Kobayashi, Kazufumi, Kondo, Takayuki, Ogasawara, Sadahisa, Chiba, Tetsuhiro, Chayama, Kazuaki, Kato, Naoya, Sakaida, Isao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124673/ https://www.ncbi.nlm.nih.gov/pubmed/34067075 http://dx.doi.org/10.3390/cancers13092247 |
Ejemplares similares
-
Impact of skeletal muscle volume on patients with BCLC stage‐B hepatocellular carcinoma undergoing sorafenib therapy
por: Saeki, Issei, et al.
Publicado: (2023) -
Management of Systemic Therapies and Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma Based on Sarcopenia Assessment
por: Yamasaki, Takahiro, et al.
Publicado: (2022) -
Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib
por: Yamamoto, Naoki, et al.
Publicado: (2016) -
Effect of body composition on survival benefit of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A comparison with sorafenib therapy
por: Saeki, Issei, et al.
Publicado: (2019) -
Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy
por: Saeki, Issei, et al.
Publicado: (2018)